What’s the current market cap for Scholar Rock stock?

Scholar Rock (SRRK) has a market cap of $5.7B as of May 22, 2026.

What is the P/E ratio for Scholar Rock stock?

The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of May 22, 2026.

Does Scholar Rock stock pay dividends?

No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of May 22, 2026.

When is the next Scholar Rock dividend payment date?

Scholar Rock (SRRK) stock does not pay dividends to its shareholders.

What is the beta indicator for Scholar Rock?

Scholar Rock (SRRK) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Scholar Rock stock | $SRRK Share Price

About Scholar Rock

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Ticker

$SRRK

Sector

Health

Primary listing

NASDAQ

Employees

289

Headquarters

Cambridge, United States

Website

www.scholarrock.com

Scholar Rock Metrics

BasicAdvanced

$5.7bn

-

-$3.43

0.71

-

What the Analysts think about Scholar Rock

Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.

Bulls say / Bears say

Scholar Rock resubmitted its Biologics License Application for apitegromab on March 31, 2026, and expects FDA acceptance within 30 days, with a PDUFA action date anticipated in late September 2026—a key regulatory milestone towards commercialization. (Investing.com)

The company secured up to $550 million in non-dilutive funding through a debt facility with Blue Owl Capital to back apitegromab’s commercial launch and pipeline development, bolstering its financial position. (Sahm Capital)

The European Medicines Agency review of apitegromab's Marketing Authorisation Application is underway, with a decision expected by mid-2026. This could position Scholar Rock for a European launch soon after U.S. approval. (Investing.com)

The FDA issued a Complete Response Letter in September 2025 due to issues at the Catalent Indiana fill-finish facility, which were unrelated to apitegromab’s safety or efficacy. Manufacturing remediation remains a major obstacle to approval. (BioPharma Dive)

The FDA sent a Warning Letter to Catalent Indiana in early 2026, heightening regulatory risk by highlighting serious manufacturing deficiencies that must be fixed before commercial production can start. (Panabee)

Scholar Rock's net loss widened in the fourth quarter of 2025, reflecting high operating costs ahead of commercialization and raising concerns about cash runway if apitegromab approval faces further delays. (Sahm Capital)

Data summarised monthly by Lightyear AI. Last updated on 22 Apr 2026.

Scholar Rock Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Scholar Rock Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Scholar Rock News

AllArticlesVideos

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·6 days ago

Scholar Rock Q1 Earnings Call Highlights

MarketBeat·2 weeks ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.